Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 9, Number 1—January 2003

Research

Cost Effectiveness of a Potential Vaccine for Human papillomavirus

Gillian D. Sanders*Comments to Author  and Al V. Taira*
Author affiliations: *Stanford University, Stanford, California, USA

Main Article

Figure 3

Sensitivity analysis: Vaccine efficacy. Effect of a change in Human papillomavirus (HPV) vaccine efficacy on the cost effectiveness of vaccination compared with current practice under varying assumptions of vaccine immunity. The triangles represent a vaccine which provides lifetime immunity to high-risk types of HPV. The circles represent a vaccine which requires booster shots every 10 years to remain effective (base-case assumption). The hatches represent a vaccine that requires booster shots e

Figure 3. Sensitivity analysis: Vaccine efficacy. Effect of a change in Human papillomavirus (HPV) vaccine efficacy on the cost effectiveness of vaccination compared with current practice under varying assumptions of vaccine immunity. The triangles represent a vaccine which provides lifetime immunity to high-risk types of HPV. The circles represent a vaccine which requires booster shots every 10 years to remain effective (base-case assumption). The hatches represent a vaccine that requires booster shots every 5 years to remain effective. The dashed line indicates the $50,000 per quality-adjusted life year cost-effectiveness threshold. The base-case value of 75% efficacy is indicated by the arrow.

Main Article

TOP